Editor-in-Chief & Deputy Editor 2019-2021





Deputy Editor:



Sponsors & Partners

Acta Gastroenterologica Belgica is supported by grants from its major sponsors


Acta Gastroenterologica Belgica is supported by grants

from its major sponsors

Dr Falk Pharma







Acta Gastro-Enterologica Belgica is published in

partnership with the following national societies








Case reports

Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review

Price: €10,00

Colorectal cancer is one of the most frequently diagnosed malignancies worldwide. One of the most important developments in the management of metastatic colorectal cancer is targeted therapy. Bevacizumab, a monoclonal antibody inhibiting VEGF induced angiogenesis, has been accepted as safe and efficient in the treatment of metastatic colorectal cancer for more than a decade. Addition of bevacizumab to fluorouracil-based chemotherapy is also associated with severe adverse events. We present a case of bevacizumab-induced bowel ischaemia associated with gastrointestinal haemorrhage. (Acta gastroenterol. belg., 2019, 82, 322-325). [Product Details...]

Cheilitis granulomatosa and Crohn’s disease : a case report

Price: €10,00

In this case report we describe the evolution of Cheilitis granulomatosa (GC) in a young patient with Crohn’s disease during treatment with anti-TNF-alfa therapy. (Acta gastroenterol. belg., 2019, 82, 326-328). [Product Details...]

Colorectal cribriform comedo-type adenocarcinoma: a distinct subtype with poor prognosis?

Price: €10,00

Colorectal cancer is one of the most commonly diagnosed cancers in the world. It is a heterogeneous disease with several histologic subtypes, and some of them are associated with adverse prognostic factors. Cribriform comedo-type adenocarcinoma (CCA) has been included as a colorectal adenocarcinoma subtype in the last World Health Organization (WHO) classification of gastrointestinal system tumors. Some authors have linked this subtype to an adverse prognosis, but to the best of our knowledge there is only one previous report assessing its histologic and prognostic features. We herein review a series of CCA of the colon, emphasizing its clinical and morphological features. (Acta gastroenterol. belg., 2019, 82, 329-332) [Product Details...]

Olmesartan-induced enteropathy treated with budesonide

Price: €10,00

Olmesartan, an angiotensin receptor blocker, is a widely spread antihypertensive drug. Seronegative villous atrophy of the small intestine due to olmesartan use was first described in 2012. We present a new case of olmesartan-induced enteropathy and compare it to recent literature. This case might suggest a use of budesonide for treatment. (Acta gastroenterol. belg., 2019, 82, 319-321). [Product Details...]

  • «« Start
  • « Prev
  • 1
  • Next »
  • End »»
Results 1 - 4 of 4